Protagonist reports MIMRYLO FDA approval, Q3 2026 results, PN-881 Phase 2b planNov 5Quarterly updatePN-881Protagonist Therapeutics, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Protagonist posts Q2 2026 profit as ICOTYDE launch and rusfertide review advanceAug 5Quarterly updateicotrokinraJohnson & Johnson